Cell Reports Medicine

Cell Reports Medicine (cell-reports-medicine)

Journal positioning

Cell Reports Medicine, an open-access journal from Cell Press and the medical sister of Cell Reports, publishes translational and clinical research with mechanistic depth across the full spectrum of human disease. Its defining character is the pairing of clinical or translational relevance with rigorous biological insight: it favors work that does not merely report a clinical observation or a candidate biomarker, but connects it to mechanism, validates it across systems, and moves toward patient impact. The journal spans oncology, immunology, metabolism, infectious disease, neurology, cardiovascular medicine, and more, and welcomes clinical-trial results, biomarker and target discovery, disease-mechanism studies in human samples, and translational technology — provided the evidence is strong and the advance is meaningful for human health. Readership is the broad translational and clinical research community.

This skill is a fit / venue-selection / re-framing tool. It does not replace the journal's current official submission guidelines. Before submitting, re-check the live author instructions on the Cell Reports Medicine (Cell Press) site.

When to trigger

• The author names Cell Reports Medicine as the target for a translational or clinical study with mechanistic depth.
• A study links a clinical observation, biomarker, or therapeutic response to an underlying biological mechanism and the author is choosing between Cell Reports Medicine and nature-medicine or science-translational-medicine.
• A solid clinical or translational result has broad interest but may not reach the top general medical journals, and the author wants a high-quality open-access Cell Press venue.
• The author needs the journal's scope, evidence bar, and desk-reject criteria before submission.

Scope & topic fit

• Translational disease mechanism: studies in human samples (patient cohorts, biopsies, organoids, primary cells) that define how a disease process works and why it matters clinically.
• Biomarker and target discovery with validation: candidate biomarkers or therapeutic targets shown to be robust, with mechanistic and cohort-level support.
• Clinical and interventional studies: trials, observational studies, and real-world analyses, especially when paired with mechanistic or correlative biology.
• Therapeutics and pharmacology: mechanism of action, resistance, combination rationale, and translational pharmacodynamics.
• Immunotherapy, precision oncology, metabolic and immune-mediated disease, infectious disease, and neurological/cardiovascular medicine.
• Translational technologies (diagnostics, delivery, computational/AI clinical tools) when validated and clinically meaningful.

Method & evidence bar

• Both relevance and rigor are required: a clinically interesting finding must be supported by strong, well-controlled evidence and, where the claim demands it, mechanistic causality (perturbation, functional validation), not correlation alone.
• Human-relevant validation strengthens claims: patient cohorts, primary samples, organoids, or appropriate in vivo models beyond cell lines.
• Clinical studies must report rigorously: pre-registration where applicable (e.g., ClinicalTrials.gov), CONSORT/STROBE-style reporting, defined endpoints, appropriate statistics, and effect sizes with confidence intervals.
• Cohort and biomarker claims require adequate sample size, and ideally independent validation cohorts; statistical reporting and multiple-testing handling are scrutinized.
• Reagent, antibody, and cell-line validation and ethics oversight (IRB/IACUC, informed consent) must be complete.
• Data and code must be deposited per Cell Press policy: omics/sequencing data in public repositories (GEO, SRA, PRIDE, dbGaP/EGA for controlled data), and analysis code made available (e.g., GitHub/Zenodo).

Structure & house style

• Cell Press article formats apply (Article and shorter Report types, plus front-matter) — re-check current article types and limits on the live site.
• The abstract and introduction must state the clinical/translational question and the advance concisely for a broad biomedical readership, with patient relevance explicit early.
• Figures must integrate clinical and mechanistic evidence: cohort/clinical panels alongside functional or molecular validation; each panel must justify its inclusion.
• A STAR Methods (or current Cell Press methods format) section is expected, with complete reagent, cohort, and statistical detail enabling reproduction; supplementary materials carry additional data.
• Key Resources and reporting-standard tables are expected; the writing is dense and significance-driven.